Clinical trial
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In…
NCT00089583 · ViiV Healthcare, Industry · Completed
Key facts
| NCT number | NCT00089583 |
|---|---|
| Title | 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection |
| Official title | A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID When Administered to HIV-1 Infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of… |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus I |
| Intervention type | Drug |
| Interventions | LEXIVA (GW433908), Ritonavir |
| Enrollment | 110 |
| Start date | Jul 1, 2004 |
| Primary completion | Mar 1, 2011 |
| Completion | Jul 1, 2013 |
| First posted | Aug 10, 2004 |
| Last update posted | Mar 7, 2017 |
| Countries | Belgium, Canada, Romania, Russia, South Africa, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: